GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellular Biomedicine Group Inc (NAS:CBMG) » Definitions » Quick Ratio

Cellular Biomedicine Group (Cellular Biomedicine Group) Quick Ratio : 0.47 (As of Sep. 2020)


View and export this data going back to 2007. Start your Free Trial

What is Cellular Biomedicine Group Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Cellular Biomedicine Group's quick ratio for the quarter that ended in Sep. 2020 was 0.47.

Cellular Biomedicine Group has a quick ratio of 0.47. It indicates that the company cannot currently fully pay back its current liabilities.

The historical rank and industry rank for Cellular Biomedicine Group's Quick Ratio or its related term are showing as below:

CBMG's Quick Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.53
* Ranked among companies with meaningful Quick Ratio only.

Cellular Biomedicine Group Quick Ratio Historical Data

The historical data trend for Cellular Biomedicine Group's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellular Biomedicine Group Quick Ratio Chart

Cellular Biomedicine Group Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.40 17.21 6.47 6.79 1.44

Cellular Biomedicine Group Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.86 1.44 1.00 0.53 0.47

Competitive Comparison of Cellular Biomedicine Group's Quick Ratio

For the Biotechnology subindustry, Cellular Biomedicine Group's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cellular Biomedicine Group's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellular Biomedicine Group's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Cellular Biomedicine Group's Quick Ratio falls into.



Cellular Biomedicine Group Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Cellular Biomedicine Group's Quick Ratio for the fiscal year that ended in Dec. 2019 is calculated as

Quick Ratio (A: Dec. 2019 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(34.03-0)/23.673
=1.44

Cellular Biomedicine Group's Quick Ratio for the quarter that ended in Sep. 2020 is calculated as

Quick Ratio (Q: Sep. 2020 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(27.871-0)/59.297
=0.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cellular Biomedicine Group  (NAS:CBMG) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Cellular Biomedicine Group Quick Ratio Related Terms

Thank you for viewing the detailed overview of Cellular Biomedicine Group's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellular Biomedicine Group (Cellular Biomedicine Group) Business Description

Traded in Other Exchanges
N/A
Address
1345 Avenue of Americas, 15th Floor, New York, NY, USA, 10105
Cellular Biomedicine Group Inc is a biotechnology company focused on the development of proprietary cell therapies for the treatment of cancer and degenerative diseases. The company has two major cell platforms: immune cell therapy for treating a broad range of cancers using cancer vaccines, Chimeric Antigen Receptor T-cell technologies, and anti-PD-1 technologies; and human-adipose-derived mesenchymal progenitor cells for treatment of joint and autoimmune diseases. The immuno-oncology and stem cell research team is based in both China and the United States.
Executives
Ag Novartis 10 percent owner LICHTSTRASSE 35, BASEL V8 CH 4056
Pharma Ag Novartis 10 percent owner LICHTSTRASSE 35, CH-4002, BASEL V8
Edward T Schafer director 1400 31ST AVENUE SW, SUITE 60, MINOT ND 58701
Wen Tao Liu director 530 UNIVERSITY AVENUE, #17 PALO ALTO CA 94301
Terry Belmont director 530 UNIVERSITY DRIVE PALO ALTO CA 94301
Au Chun Kwok Alan director C/O CELLULAR BIOMEDICINE GROUP, INC. 530 UNIVERSITY AVENUE, #17 NEW YORK NY 94301
Hansheng Zhou director 369 LUMO ROAD HONGSHAN DISTRICT WUHAN F4 430074
Gang Jacky Ji director XIXI RONGZHUANG 27-3 JINGCHANG ROAD, YUHANG DISTRICT, HANGZHOU, ZHEJIANG F4 311100
Viktor Pan 10 percent owner HELI XI LU 183 NO. 531 SHANGHAI F4 201317
Srl Opea director VIA CESARE BATTISTA 1 MILAN L6 20122
Zheng Zhou 10 percent owner FLAT B, 25/F, TOWER 6, MARINELLA 9 WELFARE ROAD, ABERDEEN HONG KONG K3 00000
Sailing Capital Overseas Investments Fund, Lp 10 percent owner C/O UNIT 2006-08, 20F HARBOUR CENTRE 25 HARBOUR ROAD WAN CHAI K3 00000
Maplebrook Ltd 10 percent owner P.O. BOX 31119 GRAND PAVILLION HIBISCUS WAY, 802 WEST BAY ROAD GRAND CAYMAN E9 KY1-1205
Tf Venture Capital Management Co., Ltd. 10 percent owner PO BOX 472, 2ND FLOOR, HARBOUR PLACE 103 SOUTH CHURCH STREET, GEORGE TOWN GRAND CAYMAN E9 KY1-1106
Winsor Capital Ltd 10 percent owner TRINITY CHAMBERS PO BOX 4301, ROAD TOWN TORTOLA D8 00000

Cellular Biomedicine Group (Cellular Biomedicine Group) Headlines

From GuruFocus